eftilagimod alpha
medsir,immutep
['sclc', 'nsclc', 'eftilagimod', 'medsir']
dr. enriqueta felip from shares data showing efficacy in terms of orr by irrecist (38.6%)/recist (37.7%) and mpfs (6.9 months) along with a safe/tolerable profile of eftilagimod alpha as 1l regimen of mnsclc irrespective of pd-l1
#asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc